Total trials
119
Active
28
Phase 3
5
Total enrollment
247,135
Pipeline matrix
Showing 19 of 19 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Doxorubicin | — | — | — | — | 3 | ||
| Pembrolizumab | — | — | — | — | — | 1 | |
| Pemetrexed | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | — | 1 | |
| Ifosfamide or dacarbazine | — | — | — | — | — | 1 | |
| At the discretion of the investigator | — | — | — | — | — | 1 | |
| Association of darolutamide and EBRT | — | — | — | — | — | 1 | |
| Association of ADT and EBRT | — | — | — | — | — | 1 | |
| Bintrafusp alfa | — | — | — | — | — | 1 | |
| Ifosfamide | — | — | — | — | — | 1 | |
| INCMGA00012 | — | — | — | — | — | 1 | |
| Association atezolizumab + BDB001 + RT | — | — | — | — | — | 1 | |
| Association atezolizumab + BDB001+ RT | — | — | — | — | — | 1 | |
| MEDI5752 | — | — | — | — | — | 1 | |
| Association of pembrolizumab + cabozantinib | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | — | 2 | |
| Immunotherapeutic Agent | — | — | — | — | — | 1 | |
| target treatment | — | — | — | — | — | 1 | |
| Liquid biopsy | — | — | — | — | — | 1 |
Next readouts
- 2025-08-06
- 2026-03
- 2026-08-27
- 2026-12
- 2026-12
- 2026-12
- 2026-12
- 2026-12-01
- 2027-01
- 2030-12-31
Top conditions
- Breast Cancer24
- Cancer12
- Prostate Cancer10
- Colorectal Cancer9
- Sarcoma6
- Lymphoma5
- Non Small Cell Lung Cancer5
- Soft Tissue Sarcoma Adult4
Frequently asked questions about Institut Bergonié
- How many clinical trials does Institut Bergonié have on ClinicalTrials.gov?
- Institut Bergonié is listed as the lead sponsor on 119 clinical trials in ClinicalTrials.gov, 28 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Institut Bergonié's trials are in Phase 3?
- 5 of Institut Bergonié's trials are in Phase 3, spread across 19 active drug programs.
- What therapeutic areas does Institut Bergonié focus on?
- Institut Bergonié's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Cancer, Prostate Cancer, Colorectal Cancer, Sarcoma.
- When are Institut Bergonié's next clinical trial readouts?
- Institut Bergonié has 10 upcoming primary-completion readouts tracked here; the soonest is “Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)”, expected around 2025-08-06.